According to BioMarin Pharmaceutical's latest financial reports the company has a price-to-book ratio of 3.01.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 3.67 | -12.21% |
2022-12-31 | 4.18 | 9.88% |
2021-12-31 | 3.80 | -1.92% |
2020-12-31 | 3.88 | -20.39% |
2019-12-31 | 4.87 | -4.78% |
2018-12-31 | 5.11 | -8.28% |
2017-12-31 | 5.58 | 8.26% |
2016-12-31 | 5.15 | -26.93% |
2015-12-31 | 7.05 | -20.1% |
2014-12-31 | 8.82 | 17.21% |
2013-12-31 | 7.53 | 23.5% |
2012-12-31 | 6.09 | 19.97% |
2011-12-31 | 5.08 | 22.28% |
2010-12-31 | 4.15 | -29.53% |
2009-12-31 | 5.89 | -8.22% |
2008-12-31 | 6.42 | -64.93% |
2007-12-31 | 18.3 | 43.5% |
2006-12-31 | 12.8 | -223.42% |
2005-12-31 | -10.3 | 70.54% |
2004-12-31 | -6.06 | -243.53% |
2003-12-31 | 4.22 | 9.79% |
2002-12-31 | 3.85 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Sanofi SNY | 1.50 | -50.00% | ๐ซ๐ท France |
Ultragenyx RARE | 12.4 | 312.52% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | 1.45 | -51.73% | ๐บ๐ธ USA |
Esperion Therapeutics ESPR | -0.9577 | -131.83% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | 17.9 | 493.70% | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | 5.07 | 68.61% | ๐บ๐ธ USA |